Medication overuse headache

electroCore Announces Issuance of Two New U.S. Patents

Retrieved on: 
Wednesday, December 7, 2022
Indigestion, A luta continua, Migraine, Neurology, Adolescence, Nerve conduction study, Patient, Hearing, NVN, Nature, Ear, Hypertension, Disclosure, Marketing, FDA, Medication overuse headache, Patent, Skin, Pain, Neck, Risk, Cluster headache, Gastroparesis, Magnetism, Tachycardia, Union, ElectroCore, Disorder, Ileus, Transcutaneous electrical nerve stimulation, IP, Indometacin, Bradycardia, ECOR, Safety, 1836 U.S. Patent Office fire, Headache, Hemicrania continua, Vagus nerve, Functional gastrointestinal disorder, Hypotension, Medical device, Pharmaceutical industry

11,511,109 entitled “Non-invasive Magnetic or Electrical Nerve Stimulation to Treat Gastroparesis, Functional Dyspepsia, and other Functional Gastrointestinal Disorders” issued on November 29, 2022.

Key Points: 
  • 11,511,109 entitled “Non-invasive Magnetic or Electrical Nerve Stimulation to Treat Gastroparesis, Functional Dyspepsia, and other Functional Gastrointestinal Disorders” issued on November 29, 2022.
  • This patent is generally related to methods for treating gastroparesis, functional dyspepsia and/or ileus with nVNS.
  • 11,517,742 entitled “Non-invasive Vagal Nerve Stimulation to Treat Disorders” issued on December 6, 2022.
  • “The issuance of these two new patents continues to broaden and strengthen the usage of our nVNS therapy across multiple indications and methods,” Dan Goldberger, Chief Executive Officer of electroCore.

gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association

Retrieved on: 
Friday, November 18, 2022
COVID-19, Hypertension, Cluster headache, Medication overuse headache, Patient, IP, Skin, Adolescence, Vagus nerve, Bradycardia, Pharmacy, Indometacin, Nature, National Coding Week, Union, Pain, Safety, Overalls, Hemicrania continua, Neurology, Migraine, NVN, APB, Tachycardia, Transcutaneous electrical nerve stimulation, CNK, Senior, A luta continua, News, Hypotension, Nerve conduction study, Hearing, Sapphire, Headache, ElectroCore, ECOR, FDA, Pharmaceutical industry

CNK numbers are unique product code identifiers allocated by the Belgian Pharmaceutical Association (APB) for products and medicines commercially available from pharmacies throughout Belgium and enables product recognition throughout the pharmaceutical network.

Key Points: 
  • CNK numbers are unique product code identifiers allocated by the Belgian Pharmaceutical Association (APB) for products and medicines commercially available from pharmacies throughout Belgium and enables product recognition throughout the pharmaceutical network.
  • We have taken a big step forward in making our therapy more widely available throughout Europe.
  • The publication of the CNK code, makes gammaCore recognized within the Belgian pharmaceutical database and therefore available via any pharmacy in Belgium.
  • When placed on a patients neck over the vagus nerve, gammaCore stimulates the nerves afferent fibers, which may lead to a reduction of pain in patients.

electroCore Announces Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Patient, Company, Migraine, Private Securities Litigation Reform Act, A luta continua, Skin, Cluster headache, Investment, Hearing, Time, Bradycardia, GAAP, NVN, Medication overuse headache, Headache, Neurology, Industry, Overalls, Indometacin, Hypotension, FDA, Adult, Webcast, Transcutaneous electrical nerve stimulation, EBITDA, Conference, Hypertension, Terminology, COVID-19, ElectroCore, Nature, Nerve conduction study, Research, Vagus nerve, Concussion, Safety, Tachycardia, Hemicrania continua, IP, Absorption, Union, Depreciation, SEC, Pain, Adolescence, Video game, Pharmaceutical industry

ROCKAWAY, N.J. , Nov. 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced third quarter 2022 financial results and provided an operational update.

Key Points: 
  • Gross margin for the third quarter of 2022 was 87%, compared to 76% in the third quarter of 2021.
  • Total operating expenses in the third quarter of 2022 were approximately $7.3 million, as compared to $5.1 million in the third quarter of 2021.
  • Research and development expense in the third quarter of 2022 was $1.6 million as compared to $470 thousand in the third quarter of 2021.
  • Selling, general and administrative expense in the third quarter of 2022 was $5.7 million as compared to $4.6 million in the third quarter of 2021.

electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC

Retrieved on: 
Tuesday, November 1, 2022
Migraine, Nature, Tachycardia, Hearing, Hypotension, Adult, Medication overuse headache, Cluster headache, Bradycardia, Pain, Partnership, SEC, GLOBE, Patient, Time, LLC, Hypertension, Industry, COVID-19, ECOR, Sapphire, ElectroCore, Nerve conduction study, Hemicrania continua, Overalls, NVN, Indometacin, Terminology, Technology, Vagus nerve, Private Securities Litigation Reform Act, FDA, Union, Skin, Neurology, Safety, Headache, Adolescence, A luta continua, Transcutaneous electrical nerve stimulation, Pharmaceutical industry

Joerns mission is to simplify care delivery so providers can focus on patients needs and payors can be confident that the best value-based therapies are available to their beneficiaries, said Doug Ferguson, Chief Strategy Officer at Joerns Healthcare.

Key Points: 
  • Joerns mission is to simplify care delivery so providers can focus on patients needs and payors can be confident that the best value-based therapies are available to their beneficiaries, said Doug Ferguson, Chief Strategy Officer at Joerns Healthcare.
  • We are excited to be working with Joerns as we expand patient access to our therapy, commentedDan Goldberger, Chief Executive Officer of electroCore.
  • Joerns Healthcare is a healthcare technology and equipment services company focused on driving the transformation of care nationally across the post-acute continuum.
  • We are simplifying the complex post-acute care world by providing the technology, professionals, products, and data to help streamline the process, so providers concentrate on care.

electroCore and Joerns Healthcare Partner to Expand Use Of gammaCore™ Vagus Nerve Technology for Headache Sufferers

Retrieved on: 
Tuesday, November 1, 2022
Migraine, Nature, Tachycardia, Hearing, Hypotension, Adult, Medication overuse headache, Cluster headache, Bradycardia, Pain, Partnership, SEC, Patient, Time, LLC, Hypertension, Industry, COVID-19, Nerve conduction study, Sapphire, ElectroCore, Hemicrania continua, Overalls, NVN, Indometacin, Terminology, Technology, Vagus nerve, Private Securities Litigation Reform Act, Company, FDA, Union, Skin, Neurology, Safety, Headache, Adolescence, A luta continua, Transcutaneous electrical nerve stimulation, Pharmaceutical industry

"We are excited to be working with Joerns as we expand patient access to our therapy," commentedDan Goldberger, Chief Executive Officer of electroCore.

Key Points: 
  • "We are excited to be working with Joerns as we expand patient access to our therapy," commentedDan Goldberger, Chief Executive Officer of electroCore.
  • Joerns Healthcare is a healthcare technology and equipment services company focused on driving the transformation of care nationally across the post-acute continuum.
  • When placed on a patient's neck over the vagus nerve, gammaCore stimulates the nerve's afferent fibers, which may lead to a reduction of pain in patients.
  • gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

electroCore Provides Select Third Quarter 2022 Financial Guidance

Retrieved on: 
Friday, October 14, 2022
International, Vagus nerve, Time, Hypertension, Migraine, Growth, Bradycardia, Patient, Tachycardia, Cluster headache, Timeline of the COVID-19 pandemic, VA, United States Department of Defense, Private Securities Litigation Reform Act, Adolescence, Company, Transcutaneous electrical nerve stimulation, Industry, Department, ECOR, Neurology, United States Department of Veterans Affairs, Department of Defence, Nerve conduction study, Hemicrania continua, Pain, Nature, Indometacin, Adult, United, NVN, Medication overuse headache, Skin, Overalls, GLOBE, European, A luta continua, ElectroCore, Headache, Hearing, Hypotension, Safety, FDA, COVID-19, Terminology, Prescription, Medical device, Video game, Pharmaceutical industry

ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the Company) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the third quarter of 2022.

Key Points: 
  • ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the Company) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the third quarter of 2022.
  • Preliminary unaudited financial guidance for the third quarter of 2022:
    Revenue: The Company anticipates reporting third quarter 2022 revenue of approximately $1,976,000.
  • 113 VA and DoD military treatment facilities purchased gammaCore products through September 30, 2022, as compared to 96 through the third quarter of 2021.
  • Cash Position: The Company ended the third quarter of 2022 with approximately $21.9 million of cash and cash equivalents, compared to $26.6 millionas of the end of the second quarter of 2022.

electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents

Retrieved on: 
Wednesday, September 21, 2022
Adult, Safety, ElectroCore, Time, Hemicrania continua, Indigestion, FDA, ECOR, Indometacin, Tachycardia, Gastroparesis, Neurodegeneration, Smartphone, 1836 U.S. Patent Office fire, Hypotension, Bradycardia, Nature, A luta continua, Migraine, NVN, Private Securities Litigation Reform Act, Cluster headache, Hearing, Hypertension, Industry, IP, Patient, Transcutaneous electrical nerve stimulation, Risk, Vagus nerve, USPTO, Method, Adolescence, Pain, Terminology, Nerve conduction study, Use, Patent, Functional gastrointestinal disorder, Alzheimer's disease, Dementia, Neurology, GLOBE, Marketing, SEC, Union, Skin, Headache, Medication overuse headache, United States patent law, Ileus, Disclosure, Medical device, Pharmaceutical industry, Residential care

11,439,818 entitled Electrical Nerve Stimulation to Treat Gastroparesis, Functional Dyspepsia, and Other Functional Gastrointestinal Disorders issued on September 13, 2022.

Key Points: 
  • 11,439,818 entitled Electrical Nerve Stimulation to Treat Gastroparesis, Functional Dyspepsia, and Other Functional Gastrointestinal Disorders issued on September 13, 2022.
  • This patent is generally related to nVNS therapies for treating post-operative ileus; and
    U.S. Patent No.
  • This patent is another in the series of patents that electroCore has received which are generally related to the use of nerve stimulators with mobile devices, such as a mobile phone.
  • We are pleased to be granted these four new patents by the USPTO, which strengthen our intellectual patent portfolio, stated Dan Goldberger, Chief Executive Officer of electroCore.

Electrocore Announces Date for Fiscal Year 2022 Annual Meeting and Deadlines for Stockholder Proposals

Retrieved on: 
Tuesday, September 20, 2022
Adult, Securities Exchange Act of 1934, Safety, ElectroCore, Time, Hemicrania continua, Corporation, Suite, FDA, ECOR, Tachycardia, Indometacin, Smartphone, Hypotension, Annual general meeting, Bradycardia, Company, Nature, A luta continua, Migraine, Annual Meetings of the International Monetary Fund and the World Bank Group, Private Securities Litigation Reform Act, Cluster headache, Hearing, Hypertension, Industry, IP, U.S. Securities and Exchange Commission, Patient, Transcutaneous electrical nerve stimulation, Risk, Vagus nerve, Adolescence, Pain, Terminology, Nerve conduction study, Neurology, Board, Security (finance), Attention, GLOBE, Marketing, Union, SEC, Medication overuse headache, Communication, Skin, Headache, NVN, Disclosure, Pharmaceutical industry, Residential care, Medical device

ROCKAWAY, N.J., Sept. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the Company), a commercial-stage bioelectronic medicine company, today announced its plans to hold its fiscal year 2022 annual meeting of stockholders (the 2022 Annual Meeting) on Friday, December 2, 2022.

Key Points: 
  • ROCKAWAY, N.J., Sept. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the Company), a commercial-stage bioelectronic medicine company, today announced its plans to hold its fiscal year 2022 annual meeting of stockholders (the 2022 Annual Meeting) on Friday, December 2, 2022.
  • The Company will publish additional details regarding the exact time, record date and matters to be voted on at the 2022 Annual Meeting in the Companys proxy statement for the 2022 Annual Meeting.
  • The Company anticipates sending proxy materials for the annual meeting to stockholders in October 2022.
  • Given that the date of the 2022 Annual Meeting differs by more than 30 days from the anniversary date of the Companys 2021 annual meeting of stockholders (the 2021 Annual Meeting), pursuant to Rule 14a-5(f) of the Securities Exchange Act of 1934, as amended (the Exchange Act), the Company is hereby providing notice of the deadlines for submission of stockholder proposals or stockholder nominations for directors to be elected to the Board of Directors of the Company (the Board).

electroCore Announces Record Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 4, 2022
FDA, Migraine, Safety, Bradycardia, Union, Nerve conduction study, ElectroCore, Industry, A luta continua, Private Securities Litigation Reform Act, IP, SEC, Investment, Sale, Adolescence, Hypotension, Absorption, Hearing, Pain, Patient, EBITDA, Stroke, Tachycardia, COVID-19, Company, Cluster headache, Transcutaneous electrical nerve stimulation, Depreciation, Neurology, Skin, Indometacin, Nature, Vagus nerve, GAAP, Research, Webcast, Headache, Hypertension, NOL, NVN, Time, Medication overuse headache, PTSD, Overalls, Conference, Adult, Terminology, Hemicrania continua, Video game, Pharmaceutical industry, Teijin

ROCKAWAY, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced second quarter 2022 financial results and provided an operational update.

Key Points: 
  • Gross margin for the second quarter of 2022 was 83%, compared to 81%in the first quarter of 2022 and 71%in the second quarter of 2021.
  • Total operating expenses in the second quarter of 2022 were approximately $7.6 million as compared to $7.1 million in the first quarter of 2022 and $6.1 million in the second quarter of 2021.
  • Research and development expense in the second quarter of 2022 was $1.3 million as compared to $934,000 in the first quarter of 2022 and $825,000 in the second quarter of 2021.
  • Selling, general and administrative expense in the second quarter of 2022 was $6.3 million as compared to $6.2 million in the first quarter of 2022 and $5.3 million in the second quarter of 2021.

electroCore Provides Select Second Quarter 2022 Financial Guidance

Retrieved on: 
Tuesday, July 12, 2022
Medication overuse headache, Overalls, Tachycardia, Transcutaneous electrical nerve stimulation, Hypotension, Bradycardia, United States Department of Veterans Affairs, Hemicrania continua, ECOR, Prescription, Timeline of the COVID-19 pandemic, Company, United, NVN, ElectroCore, Terminology, Patient, Indometacin, A luta continua, Adult, Nerve conduction study, GLOBE, COVID-19, Safety, United States Department of Defense, Hearing, Private Securities Litigation Reform Act, Migraine, Time, Adolescence, Cluster headache, International, Skin, VA, European, Pain, Vagus nerve, Department, FDA, Headache, Department of Defence, Growth, Neurology, Hypertension, Nature, Industry, Medical device, Video game, Pharmaceutical industry

Record revenue will be at least $2.1 million; approximately 65% growth over second quarter 2021

Key Points: 
  • Record revenue will be at least $2.1 million; approximately 65% growth over second quarter 2021
    ROCKAWAY, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the Company) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the second quarter of 2022.
  • Preliminary unaudited financial guidance for the second quarter of 2022:
    Revenue: The Company anticipates reporting second quarter 2022 revenue of more than $2,100,000.
  • This represents at least an 11% increase over the first quarter 2022 revenue of $1,899,000 and approximately 65% growth over the second quarter 2021 revenue of $1,269,000.
  • 106 VA and DoD military treatment facilities purchased gammaCore products through June 30, 2022, as compared to 105 through the first quarter of 2022 and 85 through the second quarter of 2021.